title: Who will benefit from treatment against EGFR?
authors.forename: Joaquín
authors.initials: J
authors.lastname: Arribas
authors.forename: José
authors.initials: J
authors.lastname: Baselga
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000276:immunology; D005260:Female; D006801:Humans; D009154:Mutation; D020794:Receptor Protein-Tyrosine Kinases / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D066246:ErbB Receptors; D020794:Receptor Protein-Tyrosine Kinases